Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan-Feb;36(1):40-48.
doi: 10.21873/invivo.12674.

Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review

Affiliations
Review

Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review

Dragos Serban et al. In Vivo. 2022 Jan-Feb.

Abstract

Background: Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.

Materials and methods: A comprehensive search was performed on PubMed, Web of Science and Google scholar.

Results: After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.

Conclusion: Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.

Keywords: Breast cancer; anastrozole; aromatase inhibitors; dry eye; endocrine therapy; ocular side-effects; review.

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest in relation to this study.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Breast cancer. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. [Last accessed on September 10, 2021]
    1. Hendrick RE, Baker JA, Helvie MA. Breast cancer deaths averted over 3 decades. Cancer. 2019;125(9):1482–1488. doi: 10.1002/cncr.31954. - DOI - PubMed
    1. Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: Incidence and survival across European countries. Breast Care (Basel) 2019;14(6):344–353. doi: 10.1159/000503219. - DOI - PMC - PubMed
    1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E, ESMO Guidelines Committee Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173. - DOI - PubMed

MeSH terms

Substances